BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months

Amyloidosis (ATTR / AL) clinical trials and catalysts

Active industry-sponsored trials on ClinicalTrials.gov for amyloidosis: 100 (50 sponsors; 24 newly posted in the last 180 days, 5 stopped in the last 180 days; 7 new-entrant sponsors). Momentum score 24, rank 16 of 91 on the disease-area ranking. As of 2026-11-18.

Phase distribution: Early Phase 1 0, Phase 1 10, Phase 2 26, Phase 3 28, Phase 4 5, N/A 31.

Most active sponsors, by phase

SponsorActive trialsBy phaseNew (window)Upcoming readouts
Alnylam Pharmaceuticals ALNY9P3 4, P2 1, NA 400
Eli Lilly and Company LLY9P3 4, P1 3, NA 1, P2 140
Alexion Pharmaceuticals, Inc.6P4 1, P3 4, P2 110
Eidos Therapeutics, a BridgeBio company4P3 3, P4 110
Colgate Palmolive CL new entrant3P4 1, P3 232
Intellia Therapeutics NTLA3NA 1, P3 200
Ionis Pharmaceuticals, Inc. IONS2P3 200
AstraZeneca AZN8NA 6, P3 1, P2 130
Novo Nordisk A/S NVO3P3 1, P2 1, P1 100
AbbVie ABBV2P3 1, P2 110
Eisai Inc.2P3 1, NA 110
Nexcella Inc.2P3 1, P2 111
Regeneron Pharmaceuticals REGN2P3 1, P2 110
Sinocelltech Ltd.1P3 100
Bayer4NA 3, P4 110
Janssen Research & Development, LLC3P1 2, P2 101
Akcea Therapeutics2NA 200
Galimedix Therapeutics Inc2P2 210
Pfizer PFE2NA 201
AC Immune SA ACIU1P2 100
Alzamend Neuro, Inc. ALZN1P2 100
Amydis Inc.1P2 101
Arctic Therapeutics new entrant1P2 111
Attralus, Inc.1P2 100
Cenna Biosciences Inc.1P1 100

New-entrant sponsors: Colgate Palmolive, Arctic Therapeutics.

Recently stopped trials

Upcoming trial readouts (next 90 days)

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2026-12 est.P2Amydis Inc.NCT05709314 A Study of AMDX-2011P in Participants With CAACerebral Amyloid Angiopathyrecruiting25
2026-12 est.P1/P2Nexcella Inc.NCT06097832 Study of NXC-201 CAR-T in Patients With Light Chain (AL) AmyloidosisLight Chain (AL) Amyloidosisactive not recruiting45
2026-12-29 est.P2Arctic TherapeuticsNCT07716865 Safety, Tolerability and Efficacy of NPI-001 in Patients With Hereditary Cystatin C Amyloid Angiopathy (HCCAA)Hereditary Cystatin C Amyloid Angiopathy (HCCAA); Hemorrhage Brain; Hemorrhage Cerebralactive not recruiting15

FDA decision events (last 12 months and upcoming)

DateEventStatusCompanyDrugSource
2026-11-27PDUFA date (company-disclosed)pendingBridgeBio Pharma, Inc. BBIOPDUFA November 27, 2026 - BridgeBio Pharma, Inc.

Readouts in the last 180 days

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2026-10-31 est.P2Neurimmune AGNCT07213583 Study of Re-Treatment With ALXN2220 in Patients With ATTR-CMAmyloid Transthyretin Cardiomyopathyactive not recruiting35
2026-09-28 est.P2Attralus, Inc.NCT05951049 A Study of AT-02 in Subjects With Systemic Amyloidosis.Amyloidosis; Systemicactive not recruiting120
2026-09 est.P3Eidos Therapeutics, a BridgeBio companyNCT04882735 Efficacy and Safety of Acoramidis (AG10) in Subjects with Transthyretin Amyloid Polyneurophathy (ATTRibute-PN)Transthyretin-Related (ATTR) Familial Amyloid Polyneuropathywithdrawn
2026-06-30 est.P2Keymed Biosciences Co.LtdNCT07039578 Study Evaluating the Efficacy and Safety of CM336 Injection in the Treatment of Light-Chain AmyloidosisPrimary Light-Chain Amyloidosisrecruiting90

Landscape counts: ClinicalTrials.gov, industry lead sponsors, active statuses, via the free hosted BioCatalystFeed MCP tool condition_landscape (query "amyloidosis"); readouts matched by condition text. Registry counts only; not a forecast.

Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA (openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score. Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP readout_calendar / fda_decisions. Not investment advice.